Scilight Press

Author Information

Received: 19 Nov 2025 | Revised: 17 Dec 2025 | Accepted: 22 Dec 2025 | Published: 26 Dec 2025

Abstract

Graphical Abstract

Image Viewer

Open in new tab

Download Image

Keywords

induced pluripotent stem cell-derived cells | embryonic stem cell-derived cells | clinical trial | age-related macular degeneration | progenitor cells

References 

• 1.

  Thomson, J.A.; Itskovitz-Eldor, J.; Shapiro, S.S.; et al. Embryonic stem cell lines derived from human blastocysts. Science 1998, 282, 1145–1147.

• 2.

  Takahashi, K.; Tanabe, K.; Ohnuki, M.; et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131, 861–872.

• 3.

  Liu, Y.; Xu, H.W.; Wang, L.; et al. Human embryonic stem cell-derived retinal pigment epithelium transplants as a potential treatment for wet age-related macular degeneration. Cell Discov. 2018, 4, 50.

• 4.

  Qiu, T.G. Transplantation of human embryonic stem cell-derived retinal pigment epithelial cells (MA09-hRPE) in macular degeneration. NPJ Regen. Med. 2019, 4, 19.

• 5.

  Li, S.Y.; Liu, Y.; Wang, L.; et al. A phase I clinical trial of human embryonic stem cell-derived retinal pigment epithelial cells for early-stage Stargardt macular degeneration: 5-years’ follow-up. Cell Proliferat. 2021, 54, e13100.

• 6.

  Takagi, S.; Mandai, M.; Gocho, K.; et al. Evaluation of transplanted autologous induced pluripotent stem cell-derived retinal pigment epithelium in exudative age-related macular degeneration. Ophthalmol. Retina 2019, 3, 850–859.

• 7.

  Hirami, Y.; Mandai, M.; Sugita, S.; et al. Safety and stable survival of stem-cell-derived retinal organoid for 2 years in patients with retinitis pigmentosa. Cell Stem Cell 2023, 30, 1585–1596 e1586.

• 8.

  da Cruz, L.; Fynes, K.; Georgiadis, O.; et al. Phase 1 clinical study of an embryonic stem cell-derived retinal pigment epithelium patch in age-related macular degeneration. Nat. Biotechnol. 2018, 36, 328–337.

• 9.

  Soomro, T.; Georgiadis, O.; Coffey, P.J.; et al. Safety, structure and function five years after hESC-RPE patch transplantation in acute neovascular AMD with submacular haemorrhage. Graefes. Arch. Clin. Exp. Ophthalmol. 2024, 262, 3057–3060.

• 10.

  da Cruz, L.; Soomro, T.; Georgiadis, O.; et al. The fate of RPE cells following hESC-RPE patch transplantation in haemorrhagic Wet AMD: Pigmentation, extension of pigmentation, thickness of transplant, assessment for proliferation and visual function-A 5 year-follow up. Diagnostics 2024, 14, 1005.

• 11.

  Kashani, A.H.; Lebkowski, J.S.; Rahhal, F.M.; et al. A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration. Sci. Transl. Med. 2018, 10, eaao4097.

• 12.

  Kashani, A.H.; Lebkowski, J.S.; Rahhal, F.M.; et al. One-year follow-up in a phase 1/2a clinical trial of an allogeneic RPE cell bioengineered implant for advanced dry age-related macular degeneration. Transl. Vis. Sci. Technol. 2021, 10, 13.

• 13.

  Kashani, A.H.; Lebkowski, J.S.; Hinton, D.R.; et al. Survival of an HLA-mismatched, bioengineered RPE implant in dry age-related macular degeneration. Stem Cell Rep. 2022, 17, 448–458.

• 14.

  Humayun, M.S.; Clegg, D.O.; Dayan, M.S.; et al. Long-term follow-up of a phase 1/2a clinical trial of a stem cell-derived bioengineered retinal pigment epithelium implant for geographic atrophy. Ophthalmology 2024, 131, 682–691.

• 15.

  Schweitzer, J.S.; Song, B.; Herrington, T.M.; et al. Personalized iPSC-derived dopamine progenitor cells for Parkinson’s disease. N. Engl. J. Med. 2020, 382, 1926–1932.

• 16.

  Kirkeby, A.; Nelander, J.; Hoban, D.B.; et al. Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD. Cell Stem Cell 2023, 30, 1299–1314 e1299.

• 17.

  Gotkine, M.; Caraco, Y.; Lerner, Y.; et al. Safety and efficacy of first-in-man intrathecal injection of human astrocytes (AstroRx(R)) in ALS patients: Phase I/IIa clinical trial results. J. Transl. Med. 2023, 21, 122.

• 18.

  Zhang, H.; Xue, Y.; Pan, T.; et al. Epicardial injection of allogeneic human-induced-pluripotent stem cell-derived cardiomyocytes in patients with advanced heart failure: Protocol for a phase I/IIa dose-escalation clinical trial. BMJ Open 2022, 12, e056264.

• 19.

  Miyagawa, S.; Kainuma, S.; Kawamura, T.; et al. Case report: Transplantation of human induced pluripotent stem cell-derived cardiomyocyte patches for ischemic cardiomyopathy. Front. Cardiovasc. Med. 2022, 9, 950829.

• 20.

  Kawamura, T.; Ito, Y.; Ito, E.; et al. Safety confirmation of induced pluripotent stem cell-derived cardiomyocyte patch transplantation for ischemic cardiomyopathy: First three case reports. Front. Cardiovasc. Med. 2023, 10, 1182209.

• 21.

  Menasche, P.; Vanneaux, V.; Hagege, A.; et al. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: First clinical case report. Eur. Heart J. 2015, 36, 2011–2017.

• 22.

  Menasche, P.; Vanneaux, V.; Fabreguettes, J.R.; et al. Towards a clinical use of human embryonic stem cell-derived cardiac progenitors: A translational experience. Eur. Heart J. 2015, 36, 743–750.

• 23.

  Menasché, P.; Vanneaux, V.; Hagège, A.; et al. Transplantation of human embryonic stem cell-derived cardiovascular progenitors for severe ischemic left ventricular dysfunction. J. Am. Coll. Cardiol. 2018, 71, 429–438.

• 24.

  Shin, J.H.; Ryu, C.M.; Yu, H.Y.; et al. Safety of human embryonic stem cell-derived mesenchymal stem cells for treating interstitial cystitis: A phase I study. Stem Cells Translational Medicine 2022, 11, 1010–1020.

• 25.

  Kelly, K.; Bloor, A.J.C.; Griffin, J.E.; et al. Two-year safety outcomes of iPS cell-derived mesenchymal stromal cells in acute steroid-resistant graft-versus-host disease. Nat. Med. 2024, 30, 1556–1558.

• 26.

  Ramzy, A.; Thompson, D.M.; Ward-Hartstonge, K.A.; et al. Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes. Cell Stem Cell 2021, 28, 2047–2061 e2045.

• 27.

  Shapiro, A.M.J.; Thompson, D.; Donner, T.W.; et al. Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device. Cell Rep. Med. 2021, 2, 100466.

• 28.

  Keymeulen, B.; De Groot, K.; Jacobs-Tulleneers-Thevissen, D.; et al. Encapsulated stem cell-derived beta cells exert glucose control in patients with type 1 diabetes. Nat. Biotechnol. 2024, 42, 1507–1514.

• 29.

  Kirkeby, A.; Main, H.; Carpenter, M. Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update. Cell Stem Cell 2025, 32, 10–37.

• 30.

  Wang, X.; Gao, M.; Wang, Y.; The progress of pluripotent stem cell-derived pancreatic beta-cells regeneration for diabetic therapy. Front. Endocrinol. 2022, 13, 927324.

• 31.

  Migliorini, A.; Nostro, M.C.; Sneddon, J.B. Human pluripotent stem cell-derived insulin-producing cells: A regenerative medicine perspective. Cell Metab. 2021, 33, 721–731.

• 32.

  Ghoneim, M.A.; Gabr, M.M.; El-Halawani, S.M.; et al. Current status of stem cell therapy for type 1 diabetes: A critique and a prospective consideration. Stem Cell Res. Ther. 2024, 15, 23.

• 33.

  Wang, G.W.; Heimendinger, P.; Ramelmeier, R.A.; et al. Pluripotent stem cell-based cell therapies: Current applications and future prospects. Curr. Opin. Biomed. Eng. 2022, 22, 100390.

• 34.

  Dang, H.P.; Chen, H.; Dargaville, T.R.; et al. Cell delivery systems: Toward the next generation of cell therapies for type 1 diabetes. J. Cell Mol. Med. 2022, 26, 4756–4767.

• 35.

  Hogrebe, N.J.; Ishahak, M.; Millman, J.R. Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes. Cell Stem Cell 2023, 30, 530–548.

• 36.

  Kim, J.Y.; Nam, Y.; Rim, Y.A.; et al. Review of the current trends in clinical trials involving induced pluripotent stem cells. Stem Cell Rev. Rep. 2022, 18, 142–154.

• 37.

  Yan, L.; Rodriguez-delaRosa, A.; Pourquie, O. Human muscle production in vitro from pluripotent stem cells: Basic and clinical applications. Semin Cell Dev. Biol. 2021, 119, 39–48.

• 38.

  Zhang, H.; Jin, Z.B. A rational consideration of the genomic instability of human-induced pluripotent stem cells for clinical applications. Sci. China Life Sci. 2023, 66, 2198–2200.

• 39.

  Park, S.J.; Kim, Y.Y.; Han, J.Y.; et al. Advancements in human embryonic stem cell research: Clinical applications and ethical issues. Tissue Eng. Regen. Med. 2024, 21, 379–394.

• 40.

  Luce, E.; Messina, A.; Duclos-Vallee, J.C.; et al. Advanced techniques and awaited clinical applications for human pluripotent stem cell differentiation into hepatocytes. Hepatology 2021, 74, 1101–1116.

• 41.

  Pendse, S.; Vaidya, A.; Kale, V. Clinical applications of pluripotent stem cells and their derivatives: Current status and future perspectives. Regen. Med. 2022, 17, 677–690.

• 42.

  Cong, X.; Zhang, S.M.; Ellis, M.W.; et al. Large animal models for the clinical application of human induced pluripotent stem cells. Stem Cells Dev. 2019, 28, 1288–1298.

• 43.

  Kelly, M.I.; Albahrani, M.; Castro, C.; et al. Importance of evaluating protein glycosylation in pluripotent stem cell-derived cardiomyocytes for research and clinical applications. Pflugers Arch. 2021, 473, 1041–1059.

• 44.

  Okano, H.; Morimoto, S.; Kato, C.; et al. Induced pluripotent stem cells-based disease modeling, drug screening, clinical trials, and reverse translational research for amyotrophic lateral sclerosis. J. Neurochem. 2023, 167, 603–614.

• 45.

  Lam, C.K.; Wu, J.C. Clinical Trial in a Dish: Using patient-derived induced pluripotent stem cells to identify risks of drug-induced cardiotoxicity. Arterioscler Thromb. Vasc. Biol. 2021, 41, 1019–1031.

• 46.

  Bretzner, F.; Gilbert, F.; Baylis, F.; et al. Target populations for first-in-human embryonic stem cell research in spinal cord injury. Cell Stem Cell 2011, 8, 468–475.

• 47.

  Manley, N.C.; Priest, C.A.; Denham, J.; et al. Human embryonic stem cell-derived oligodendrocyte progenitor cells: Preclinical efficacy and safety in cervical spinal cord injury. Stem Cells Transl. Med. 2017, 6, 1917–1929.

• 48.

  Priest, C.A.; Manley, N.C.; Denham, J.; et al. Preclinical safety of human embryonic stem cell-derived oligodendrocyte progenitors supporting clinical trials in spinal cord injury. Regen. Med. 2015, 10, 939–958.

• 49.

  Higuchi, A.; Kumar, S.S.; Benelli, G.; et al. Biomaterials used in stem cell therapy for spinal cord injury. Prog. Mater. Sci. 2019, 103, 374–424.

• 50.

  Nakamura, M.; Okano, H. Cell transplantation therapies for spinal cord injury focusing on induced pluripotent stem cells. Cell Res. 2013, 23, 70–80.

• 51.

  Schwartz, S.D.; Hubschman, J.P.; Heilwell, G.; et al. Embryonic stem cell trials for macular degeneration: A preliminary report. Lancet 2012, 379, 713–720.

• 52.

  Schwartz, S.D.; Regillo, C.D.; Lam, B.L.; et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: Follow-up of two open-label phase 1/2 studies. Lancet 2015, 385, 509–516.

• 53.

  Menasche, P. Cell therapy with human ESC-derived cardiac cells: Clinical perspectives. Front. Bioeng. Biotechnol. 2020, 8, 601560.

• 54.

  Bloor, A.J.C.; Patel, A.; Griffin, J.E.; et al. Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: A phase I, multicenter, open-label, dose-escalation study. Nat. Med. 2020, 26, 1720–1725.

• 55.

  Nie, W.B.; Zhang, D.; Wang, L.S. Growth factor gene-modified mesenchymal stem cells in tissue regeneration. Drug Des. Devel. Ther. 2020, 14, 1241–1256.

• 56.

  Kimbrel, E.A.; Lanza, R. Current status of pluripotent stem cells: Moving the first therapies to the clinic. Nat. Rev. Drug Discov. 2015, 14, 681–692.

• 57.

  Carr, A.J.; Smart, M.J.; Ramsden, C.M.; et al. Development of human embryonic stem cell therapies for age-related macular degeneration. Trends Neurosci. 2013, 36, 385–395.

• 58.

  Higuchi, A.; Kumar, S.S.; Benelli, G.; et al. Stem cell therapies for reversing vision loss. Trends Biotechnol. 2017, 35, 1102–1117.

• 59.

  Strauss, O. The retinal pigment epithelium in visual function. Physiol. Rev. 2005, 85, 845–881.

• 60.

  Kim, J.Y.; Zhao, H.; Martinez, J.; et al. Noncanonical autophagy promotes the visual cycle. Cell 2013, 154, 365–376.

• 61.

  Mandai, M.; Watanabe, A.; Kurimoto, Y.; et al. Autologous induced stem-cell-derived retinal cells for macular degeneration. N. Engl. J. Med. 2017, 376, 1038–1046.

• 62.

  Mehat, M.S.; Sundaram, V.; Ripamonti, C.; et al. Transplantation of human embryonic stem cell-derived retinal pigment epithelial cells in macular degeneration. Ophthalmology 2018, 125, 1765–1775.

• 63.

  Chen, Q.; Deng, T.; Han, D. Testicular immunoregulation and spermatogenesis. Semin. Cell Dev. Biol. 2016, 59, 157–165.

• 64.

  Zhou, R.; Caspi, R.R. Ocular immune privilege. F1000 Biol. Rep. 2010, 2, 3.

• 65.

  Taylor, A.W. Ocular immune privilege and transplantation. Front. Immunol. 2016, 7, 37.

• 66.

  Benque, I.J.; Xia, P.; Shannon, R.; et al. The neuropeptides of ocular immune privilege, alpha-MSH and NPY, suppress phagosome maturation in macrophages. Immunohorizons 2018, 2, 314–323.

• 67.

  Forrester, J.V.; McMenamin, P.G.; Dando, S.J. CNS infection and immune privilege. Nat. Rev. Neurosci. 2018, 19, 655–671.

• 68.

  Rustenhoven, J. A privileged brain. Science 2021, 374, 548.

• 69.

  Castellani, G.; Croese, T.; Peralta Ramos, J.M.; et al. Transforming the understanding of brain immunity. Science 2023, 380, eabo7649.

• 70.

  Soma, T.; Oie, Y.; Takayanagi, H.; et al. Induced pluripotent stem-cell-derived corneal epithelium for transplant surgery: A single-arm, open-label, first-in-human interventional study in Japan. Lancet 2024, 404, 1929–1939.

• 71.

  Silver, S.E.; Barrs, R.W.; Mei, Y. Transplantation of human pluripotent stem cell-derived cardiomyocytes for cardiac regenerative therapy. Front. Cardiovasc. Med. 2021, 8, 707890.

• 72.

  Soma, Y.; Morita, Y.; Kishino, Y.; et al. The present state and future perspectives of cardiac regenerative therapy using human pluripotent stem cells. Front. Cardiovasc. Med. 2021, 8, 774389.

• 73.

  Bryl, R.; Kulus, M.; Bryja, A.; et al. Cardiac progenitor cell therapy: Mechanisms of action. Cell Biosci. 2024, 14, 30.

• 74.

  Okano, S.; Shiba, Y. Therapeutic potential of pluripotent stem cells for cardiac repair after myocardial infarction. Biol. Pharm. Bull. 2019, 42, 524–530.

• 75.

  Selvakumar, D.; Clayton, Z.E.; Prowse, A.; et al. Cellular heterogeneity of pluripotent stem cell-derived cardiomyocyte grafts is mechanistically linked to treatable arrhythmias. Nat. Cardiovasc. Res. 2024, 3, 145–165.

• 76.

  Nakamura, K.; Neidig, L.E.; Yang, X.; et al. Pharmacologic therapy for engraftment arrhythmia induced by transplantation of human cardiomyocytes. Stem Cell Rep. 2021, 16, 2473–2487.

• 77.

  Shiba, Y.; Gomibuchi, T.; Seto, T.; et al. Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts. Nature 2016, 538, 388–391.

• 78.

  Romagnuolo, R.; Masoudpour, H.; Porta-Sanchez, A.; et al. Human embryonic stem cell-derived cardiomyocytes regenerate the infarcted pig heart but induce ventricular tachyarrhythmias. Stem Cell Rep. 2019, 12, 967–981.

• 79.

  Chong, J.J.; Yang, X.; Don, C.W.; et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 2014, 510, 273–277.

• 80.

  Tiburcy, M.; Hudson, J.E.; Balfanz, P.; et al. Defined engineered human myocardium with advanced maturation for applications in heart failure modeling and repair. Circulation 2017, 135, 1832–1847.

• 81.

  Schulz, T.C. Concise Review: Manufacturing of pancreatic endoderm cells for clinical trials in type 1 diabetes. Stem Cells Transl. Med. 2015, 4, 927–931.

• 82.

  Pagliuca, F.W.; Millman, J.R.; Gurtler, M.; et al. Generation of functional human pancreatic beta cells in vitro. Cell 2014, 159, 428–439.

• 83.

  Rezania, A.; Bruin, J.E.; Arora, P.; et al. Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat. Biotechnol. 2014, 32, 1121–1133.

• 84.

  Mimeault, M.; Batra, S.K. Great promise of tissue-resident adult stem/progenitor cells in transplantation and cancer therapies. Adv. Exp. Med. Biol. 2012, 741, 171–186.

• 85.

  Zhao, Z.; Chen, X.; Dowbaj, A.M.; et al. Organoids. Nat. Rev. Methods Primers 2022, 2, 94.

• 86.

  Pullen, L.C. Stem cell-derived pancreatic progenitor cells have now been transplanted into patients: Report from IPITA 2018. Am. J. Transplant. 2018, 18, 1581–1582.

• 87.

  Bhargava, R.; Mitsides, N.; Saif, I.; et al. C-peptide and combined kidney-pancreas transplantation. NDT Plus 2009, 2, 489–492.

• 88.

  Olanow, C.W.; Goetz, C.G.; Kordower, J.H.; et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann. Neurol. 2003, 54, 403–414.

• 89.

  Freed, C.R.; Greene, P.E.; Breeze, R.E.; et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N. Engl. J. Med. 2001, 344, 710–719.

• 90.

  Barker, R.A.; Barrett, J.; Mason, S.L.; et al. Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson’s disease. Lancet Neurol. 2013, 12, 84–91.

• 91.

  Piccini, P.; Brooks, D.J.; Bjorklund, A.; et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson’s patient. Nat. Neurosci. 1999, 2, 1137–1140.

• 92.

  Kordower, J.H.; Freeman, T.B.; Snow, B.J.; et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson’s disease. N. Engl. J. Med. 1995, 332, 1118–1124.

• 93.

  Park, S.; Park, C.W.; Eom, J.H.; et al. Preclinical and dose-ranging assessment of hESC-derived dopaminergic progenitors for a clinical trial on Parkinson’s disease. Cell Stem Cell 2024, 31, 25–38 e28.

• 94.

  Tabar, V.; Sarva, H.; Lozano, A. M.; et al. Phase I trial of hES cell-derived dopaminergic neurons for Parkinson's disease. Nature 2025, 641, 978–983.

• 95.

  Santos Garcia, D.; De Deus Fonticoba, T.; Paz Gonzalez, J.M.; et al. Staging Parkinson’s disease combining motor and nonmotor symptoms correlates with disability and quality of life. Parkinsons Dis. 2021, 2021, 8871549.

• 96.

  Perlmutter, J.S. Assessment of Parkinson disease manifestations. Curr. Protoc. Neurosci. 2009, 10, 10.1.1–10.1.14.

• 97.

  Sawamoto, N.; Doi, D.; Nakanishi, E.; et al. Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson’s disease. Nature 2025, 641, 971–977.

• 98.

  Liu, Q.; Liu, J.; Guo, M.; et al. Comparison of retinal degeneration treatment with four types of different mesenchymal stem cells, human induced pluripotent stem cells and RPE cells in a rat retinal degeneration model. J. Transl. Med. 2023, 21, 910.

• 99.

  Han, Y.; Yang, J.; Fang, J.; et al. The secretion profile of mesenchymal stem cells and potential applications in treating human diseases. Signal Transduct. Target. Ther. 2022, 7, 92.

• 100.

  Dabrowska, S.; Andrzejewska, A.; Janowski, M.; et al. Immunomodulatory and regenerative effects of mesenchymal stem cells and extracellular vesicles: Therapeutic outlook for inflammatory and degenerative diseases. Front. Immunol. 2020, 11, 591065.

• 101.

  Trigo, C.M.; Rodrigues, J.S.; Camoes, S.P.; et al. Mesenchymal stem cell secretome for regenerative medicine: Where do we stand? J. Adv. Res. 2025, 70, 103–124.

• 102.

  Wang, Y.; Fang, J.; Liu, B.; et al. Reciprocal regulation of mesenchymal stem cells and immune responses. Cell Stem Cell 2022, 29, 1515–1530.

• 103.

  Margiana, R.; Markov, A.; Zekiy, A.O.; et al. Clinical application of mesenchymal stem cell in regenerative medicine: A narrative review. Stem Cell Res. Ther. 2022, 13, 366.

• 104.

  Tian, Z.; Wang, C.K.; Lin, F.L.; et al. Effect of extracellular matrix proteins on the differentiation of human pluripotent stem cells into mesenchymal stem cells. J. Mater. Chem. B 2022, 10, 5723–5732.

• 105.

  Nosoudi, N.; Hart, C.; McKnight, I.; et al. Differentiation of adipose-derived stem cells to chondrocytes using electrospraying. Sci. Rep. 2021, 11, 24301.

• 106.

  Ye, Q.; Sung, T.C.; Yang, J.M.; et al. Generation of universal and hypoimmunogenic human pluripotent stem cells. Cell Prolif. 2020, 53, e12946.

• 107.

  Malik, N.N.; Jenkins, A.M.; Mellon, J.; et al. Engineering strategies for generating hypoimmunogenic cells with high clinical and commercial value. Regen. Med. 2019, 14, 983–989.

• 108.

  Feucht, J.; Sun, J.; Eyquem, J.; et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat. Med. 2019, 25, 82–88.

• 109.

  Mandal, M.; Clarke, R.; van der Stegen, S.; et al. FT819 path to IND: First-of-kind off-the-shelf CAR19 T-cell for B cell malignancies. Cancer Res. 2020, 80, 3245.

• 110.

  Davila, M.L.; Brentjens, R.J. CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia. Clin. Adv. Hematol. Oncol. 2016, 14, 802–808.

• 111.

  Bove, C.; Arcangeli, S.; Falcone, L.; et al. CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses. J. Immunother. Cancer 2023, 11, e005878.

• 112.

  Tao, Z.; Chyra, Z.; Kotulova, J.; et al. Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies. Blood Cancer J. 2024, 14, 213.

• 113.

  Sterner, R.C.; Sterner, R.M. CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer J. 2021, 11, 69.

• 114.

  Mackensen, A.; Muller, F.; Mougiakakos, D.; et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 2022, 28, 2124–2132.

• 115.

  Holley, S.M.; Reidling, J.C.; Cepeda, C.; et al. Transplanted human neural stem cells rescue phenotypes in zQ175 Huntington’s disease mice and innervate the striatum. Mol. Ther. 2023, 31, 3545–3563.

• 116.

  Reidling, J.C.; Relano-Gines, A.; Holley, S.M.; et al. Human neural stem cell transplantation rescues functional deficits in R6/2 and Q140 Huntington’s disease Mice. Stem Cell Rep. 2018, 10, 58–72.

• 117.

  Nicholas, C.R.; Chen, J.; Tang, Y.; et al. Functional maturation of hPSC-derived forebrain interneurons requires an extended timeline and mimics human neural development. Cell Stem Cell 2013, 12, 573–586.